2019-2021 Drug Discovery for Neurodegeneration Conferences

项目摘要/摘要 在将基础研究转化为小说方面，存在着有充分证据的知识和资源缺口 治疗学。在制药行业之外，很少有机会 下一代科学领袖将了解药物发现和开发过程 总的来说，尤其是对于神经退行性疾病。为了满足这种需求，阿尔茨海默氏症 药物发现基金会(ADDF)为 神经退行性变(DDND)会议，自成立以来，已有1698人参加 成立于2007年。ADDF申请U13合作协议会议赠款，为期三年 多年来对定于2019年3月在南加州地区举行的DDND大会的支持； 2020年3月在佛罗里达州迈阿密或华盛顿特区；2021年3月在南加州地区。 这些说教会议的目标与美国国立卫生研究院的倡议是一致的 2012和2015阿尔茨海默病研究峰会：弥合药物方面的知识鸿沟 神经退行性疾病的发现；将跨学科的科学家聚集在一起 鼓励技能和学科相结合的新方法；并提供网络机会 让这些科学家交流思想和资源。 这些会议将为与会者提供关于以下方面的基本知识和资源 开发治疗和预防神经退行性疾病的新药，并将解决 与以下分主题相关的挑战：开始药物发现 运动；药物发现：从领先到临床候选；加速治疗进入 临床试验；针对中枢神经系统靶点的策略：案例研究；以及建立 基础设施将科学商业化为产品。讨论将包括相关的 例子集中在神经退行性疾病的小分子和生物发展方面。 课程将由20分钟的演讲和10分钟的问答组成，该计划将 包括网络会议、指导会议、年轻调查人员的海报会议、 还有一个早期的调查员职业小组。 关于公私伙伴关系，亚洲发展基金将邀请21个国际公认的 来自学术界、工业界和美国国立卫生研究院的科学家担任主席或演讲人。我们有 召集了一个科学咨询委员会，该委员会同意参加未来三年的 三年来协助各次会议的发展。预计这些会议将 每年为150名来自不同背景的科学家提供服务，包括女性、少数族裔、 年轻/初级调查人员和研究生。

PROJECT SUMMARY/ABSTRACT There is a well-documented knowledge and resource gap in translating basic research into novel therapeutics. Outside of the pharmaceutical industry, there are very few opportunities for the next generation of scientific leaders to learn about the drug discovery and development process in general, and particularly for neurodegenerative diseases. To meet this need, the Alzheimer’s Drug Discovery Foundation (ADDF) developed the annual Drug Discovery for Neurodegeneration (DDND) conference, which has reached 1,698 participants since its inception in 2007. The ADDF requests a U13 Cooperative Agreement conference grant for three years of support for its DDND conference, scheduled for the Southern CA area in March 2019; Miami, FL or Washington DC in March 2020; and the Southern CA area in March 2021. The goals of these didactic conferences are consistent with the initiatives set forth at the NIH’s 2012 and 2015 Alzheimer’s Disease Research Summits: to bridge the knowledge gap in drug discovery for neurodegenerative diseases; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. These conferences will provide participants with fundamental knowledge and resources on developing new drugs to treat and prevent neurodegenerative diseases, and will address the challenges associated with the following sub-topics: Embarking on a Drug Discovery Campaign; Drug Discovery: From Lead to Clinical Candidate; Accelerating Therapies into Clinical Trials; Strategies for CNS Targets: Case Study Examples; and Building the Infrastructure to Commercialize Science into Products. Discussions will include relevant examples focused on small molecule and biologic development for neurodegenerative diseases. Sessions will consist of 20-minute presentations with 10-minute Q&As, and the program will include sessions for networking, mentoring, poster sessions presented by young investigators, and an early investigator career panel. With respect to public-private partnerships, the ADDF will invite 21 internationally recognized scientists from academia, industry, and the NIH to serve as chairs or speakers. We have assembled a Scientific Advisory Committee that has agreed to participate for the next three years to assist in the development of the conferences. It is anticipated that these conferences will serve 150 scientists annually from diverse backgrounds, including women, minorities, young/junior investigators, and graduate students.